Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results ...

Morgan Stanley raised the firm’s price target on Sana Biotechnology (SANA) to $12 from $9 and keeps an Overweight rating on the shares. Based ...

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Sana Biotechnology (NASDAQ:SANA – Free Report) had its price target boosted by HC Wainwright from $8.00 to $11.00 in a report ...

Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.99%. The profit margin, also known as the revenue ratio or gross profit ratio ...

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Shares of Sana Biotechnology surged after the company released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The stock more than tripled, up 265% ...